Products

Zavegepant (CAS 1337918-83-8) is a potent, orally active calcitonin gene-related peptide (CGRP) receptor antagonist developed for the acute treatment of migraine. Chemically known as N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, Zavegepant features a complex molecular architecture incorporating a piperidine carboxamide core linked to an indazole moiety and a quinolinone scaffold.

Trifarotene (CD5789) is a potent and selective retinoic acid receptor gamma (RARγ) agonist featuring a unique terphenyl core structure with a 4′-(2-hydroxyethoxy) substituent and a 4″-(pyrrolidin-1-yl)-3″-(tert-butyl) substitution pattern . Structurally, the molecule consists of a [1,1′:3′,1″-terphenyl]-4-carboxylic acid scaffold with three distinct aromatic rings strategically functionalized to confer exceptional RARγ selectivity .

Etrasimod (APD334) is a potent, orally bioavailable, and selective antagonist of the sphingosine-1-phosphate (S1P) receptors S1P₁, S1P₄, and S1P₅, featuring a unique cyclopenta[b]indole core structure with a trifluoromethyl-substituted benzyl ether side chain . Structurally, the molecule consists of a (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl acetic acid scaffold, with the R stereochemistry at the C3 position being critical for receptor binding .

Etrasimod arginine is the L-arginine salt form of the selective S1P receptor modulator etrasimod (APD334), designed to enhance the solubility and formulation characteristics of the active pharmaceutical ingredient . Structurally, the salt consists of the (3R)-7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-ylacetate anion paired with a protonated L-arginine cation in a 1:1 stoichiometric ratio .

Ensifentrine (RPL554) is a first-in-class, inhaled dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), featuring a unique pyrimido[6,1-a]isoquinolin-4-one core structure with a 9,10-dimethoxy substitution pattern and a 2-(2,4,6-trimethylphenyl)imino side chain .

Dotinurad (FYU-981) is a novel selective urate reabsorption inhibitor featuring a phenol derivative core structure with a 1,1-dioxo-1,2-dihydro-3H-1,3-benzothiazole scaffold . Structurally, the molecule consists of a dichlorohydroxyphenyl ketone moiety linked to a benzothiazole ring system bearing a sulfone group at the 1,1-dioxide position .